These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1219 related articles for article (PubMed ID: 29935900)

  • 1. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D
    Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CDK4/6 pathways and beyond in breast cancer.
    Ribnikar D; Volovat SR; Cardoso F
    Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development of CDK4/6 inhibitor for breast cancer.
    Iwata H
    Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
    Hecht KA; Selby C
    Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
    Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
    Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
    Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value.
    Niraula S
    Breast; 2019 Feb; 43():81-84. PubMed ID: 30513476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
    Vidula N; Rugo HS
    Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
    Corona SP; Generali D
    Drug Des Devel Ther; 2018; 12():321-330. PubMed ID: 29497278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances of highly selective CDK4/6 inhibitors in breast cancer.
    Xu H; Yu S; Liu Q; Yuan X; Mani S; Pestell RG; Wu K
    J Hematol Oncol; 2017 Apr; 10(1):97. PubMed ID: 28438180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
    Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.